President John Lai Discusses Current Auditing State, the New Kush Product and the Company’s New Additions
GlobeNewswire•September 28, 2017
Minneapolis, MN., Sept. 28, 2017 (GLOBE NEWSWIRE) — John Lai, President of PetVivo Holdings Inc. (OTCPink:PETV) interviews on the Uptick Network Stock Day Podcast with host Everett Jolly. In the beginning of the interview, Mr. Lai discusses the important addition of CEO Wes Hayne and how the auditing process of the company financials is coming to a close. Mr. Lai later discusses the new CFO and how Cindy Jenkins brings the proper controls with her to bring PetVivo current and how she will be able to keep it current with future filings. Mr. Lai also briefly discusses the new Kush commercial launch and later in the interview talks about when the revenues will hit the income statement after launch of this product. Furthermore, Mr. Lai highlights the addition of two outside independent directors to the company and elaborates on the experienced back ground that these two individuals will be bringing to PetVivo.
In closing, President John Lai states, “We feel we have put the right team together to execute and move this company forward for quite a period of time to manage the growth that we anticipate with the launch of commercial products that is disruptive to the industry of how you treat osteoarthritis.”
To listen to the full interview please click here or the following link:
About PetVivo Holdings, Inc.
PetVivo Holdings, Inc. (OTC PINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.
PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes, and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for launch later this year.
The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including cardiovascular, orthopedic, urology and aesthetics.
Forward-Looking Commercial Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.
Source: Uptick Newswire